Key points are not available for this paper at this time.
Design
Guideline
Answers are grounded in this paper and cite their sources.
Strengthens GDMT implementation in HF practice; reinforces 2016 guidelines and extends research on optimized regimens.
No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
No takes yet. Share an insight, caveat, or question.
Yancy et al. (2016) studied this question. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are key pharmacological therapies updated in the 2016 ACC/AHA/HFSA guidelines for the management of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: